Physician profile

Daniel Lapidus

Pediatrics · Toms River, NJ

NPI 1770515819

$298.94

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$30.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Supernus Pharmaceuticals, INC. $74.35 2021
Merck Sharp & Dohme LLC $47.46 2019-2020
Shire North American Group INC $36.55 2019
Ironshore Pharmaceuticals INC. $25.21 2019-2020
Ultragenyx Pharmaceutical INC. $24.90 2022
Pfizer INC. $20.97 2019
Takeda Pharmaceuticals U.S.A., INC. $16.45 2023
Corium, LLC $14.04 2022
Kyowa Kirin, INC. $13.74 2023 Crysvita
Phadia US INC. $13.43 2019
Genentech USA, INC. $11.84 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Lapidus

$298.94

in general payments reported 2019-2025

Years
2019-2023
Top company
Supernus Pharmaceuticals, INC.

https://glasscript.com/doctor/35048/daniel-lapidus

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.